- Home
- HMST vs PROK Comparison
HMST vs PROK Comparison
Compare HMST & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- PROK
- Stock Information
- Founded
- HMST 1921
- PROK 2015
- Country
- HMST United States
- PROK United States
- Employees
- HMST N/A
- PROK N/A
- Industry
- HMST Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMST Finance
- PROK Health Care
- Exchange
- HMST Nasdaq
- PROK Nasdaq
- Market Cap
- HMST 287.6M
- PROK 237.4M
- IPO Year
- HMST 2012
- PROK N/A
- Fundamental
- Price
- HMST $11.04
- PROK $1.53
- Analyst Decision
- HMST Buy
- PROK Buy
- Analyst Count
- HMST 2
- PROK 5
- Target Price
- HMST $14.75
- PROK $4.50
- AVG Volume (30 Days)
- HMST 166.8K
- PROK 500.5K
- Earning Date
- HMST 01-27-2025
- PROK 11-12-2024
- Dividend Yield
- HMST N/A
- PROK N/A
- EPS Growth
- HMST N/A
- PROK N/A
- EPS
- HMST N/A
- PROK N/A
- Revenue
- HMST $169,710,000.00
- PROK N/A
- Revenue This Year
- HMST N/A
- PROK N/A
- Revenue Next Year
- HMST $12.08
- PROK N/A
- P/E Ratio
- HMST N/A
- PROK N/A
- Revenue Growth
- HMST N/A
- PROK N/A
- 52 Week Low
- HMST $8.09
- PROK $1.18
- 52 Week High
- HMST $16.10
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- HMST 42.73
- PROK 36.04
- Support Level
- HMST $10.54
- PROK $1.70
- Resistance Level
- HMST $11.95
- PROK $2.03
- Average True Range (ATR)
- HMST 0.44
- PROK 0.19
- MACD
- HMST -0.02
- PROK -0.06
- Stochastic Oscillator
- HMST 35.06
- PROK 8.33
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.